Biologic medicines and immunotherapy are front and center amongst many of the R&D strategies and platforms for the industry’s leading developers.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
Executives from 2017 Manny Award winners/finalists and other healthcare communications agencies participated in this Q&A forum of industry topics.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
For many of the healthcare advertising agencies featured within this annual special report, 2016 was another year of growth and change. With the election of Donald Trump as president of the United States and the United Kingdom’s Brexit vote to exit the European Union, the year also introduced uncertainty to agencies and their clients.
The industry’s patent cliffs have become less steep, but the Affordable Care Act will give pharma new challenges.
Fluidity was the state of pharmaceutical advertising in 2013, as agencies shifted their operations, personnel, and tactics to meet the needs of their clients, driven by the pace of digital.
The worldwide drug-delivery arena is growing each year as the increasing aging population is in need of improved methods of administration for products and therapies.
From big pharma to smaller specialty entities, contract manufacturing serves as a strategy for various industry players.
The global market for consumer-care products generated slower growth in 2010 than during the previous year, partially because of a weaker flu season in North America and Europe.
Big Pharma started the new decade where it left off in 2009 by continuing to conduct a flurry of deals amongst each other and with many other types of companies throughout the healthcare industry.